The Devil Is in the Due Diligence

By Thomas Maeder

Know when to hold ‘em, know when to fold ‘em.

In just a couple of weeks, MedTech Intelligence is hosting the MedTech Due Diligence conference in Boston. We’re bringing together a mix of didactic sessions with discussions, breakout working groups, and case studies, led by senior professionals who have gone through mergers and acquisitions and seen both the good and the bad, focuses on those issues unique to medical technology companies. Here are five reasons you need to come to the program in Boston:

  • Meet top level speakers who have been through it all
  • Identify the hidden areas where problems occur
  • Learn best practices for performing due diligence
  • Understand how to analyze and apply the due diligence results
  • Learn from others’ successes and mistakes

MedTech Due Diligence Conference, July 14-15, 2016 | Boston, MA | LEARN MORE

Related Articles

  • FDA Logo

    Beginning October 1, 2023, the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot will expand to include the Office of Neurological and Physical Medicine Devices (OHT5).  

  • Daniel Lace

    “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

  • Veranex and Fusion logos

    The acquisition expands Veranex’s footprint for product design engineering services across the U.S., with combined company offices now in the Eastern, Central, and Western regions

  • Avania and MAXIS logos

    The acquisition brings MAXIS’ expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management to Avania’s contract research and MedTech development capabilities.

About The Author

Tom Maeder, MedTech Intelligence